A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib

In non-small cell lung cancer (NSCLC), driver gene alterations, such as EGFR, ALK, MET, and ROS1, are usually mutually exclusive. Few clinical cases with co-existing ROS1 fusion and de-novo MET amplification have been reported. In addition, the efficacy of crizotinib in Chinese patients with driver...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, You-cai, Wang, Wen-xian, Xu, Chun-wei, Zhuang, Wu, Song, Zheng-bo, Du, Kai-qi, Chen, Gang, Lv, Tang-feng, Song, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Bedside to Bench Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301800/
https://www.ncbi.nlm.nih.gov/pubmed/30095326
http://dx.doi.org/10.1080/15384047.2018.1491506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301800/
https://www.ncbi.nlm.nih.gov/pubmed/30095326
http://dx.doi.org/10.1080/15384047.2018.1491506

Ejemplares similares